Breast Cancer Data Hub News

Addressing Knowledge Gaps in Metastatic Triple-Negative Breast Cancer Treatment and Care

An educational activity provided by i3 Health has delivered significant improvement in knowledge regarding treatment advances and personalized care for patients with metastatic triple-negative breast cancer (TNBC). Breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United Stat...

Uncovering Racial Disparities Experienced in Breast Cancer Patients With Yara Abdou, MD

Lyn Brook

Expert Analysis

At the recent San Antonio Breast Cancer Symposium (SABCS), Yara Abdou, MD, Assistant Professor of Hematology and Oncology and Medical Oncologist at The University of North Carolina School of Medicine, presented her team's research on the disparities that Black women with breast cancer experience. Afterwards, she spoke with Oncology Data Advisor to ...

Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer

Lyn Brook

Practice Patterns

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer dea...

Trastuzumab Deruxtecan Approved for Treatment of HER2-Low Breast Cancer

Lyn Brook

FDA Updates

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–low breast cancer. This treatment is indicated for patients who have previously undergone chemotherapy in the metastatic setting or who developed disease recurrence ...

Fam-Trastuzumab Deruxtecan-nxki Approved for Treatment of Breast Cancer

Lyn Brook

FDA Updates

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for treatment of patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The approval is specific to individuals who have had prior treatment with an anti–HER2-based regimen in the metastatic, neoadjuvant, o...

About

Resources

Subscribe

Follow Us